This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The company expects to launch this product through its marketing partner in the near future
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Morepen Laboratories approves hiving off of medical devices business
Cenexi is committed to working closely with the ANSM to address the observations
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The inspection was concluded with two 483 observations
Subscribe To Our Newsletter & Stay Updated
